Navigation Links
Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases
Date:7/7/2009

cancer, for which denosumab is administered twice yearly subcutaneously at a 60 mg dose. The Prolia(TM) trade name is only for these indications and may not apply for other indications of denosumab.

(1) Capanna R, Coia LR, Coleman R. et al. eds. Textbook of Bone Metastases. Hoboken, NJ: Edition: John Wiley and Sons; 2005:105.

(2) Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002 Aug;2(8):584-93.

(3) Schulman K and Kohles J. Cancer. 2007;109:2334-2342

(4) GVD/Barber ISPOR 2008 Poster; Schulman 2007; Delea et al. 2006 

    Amgen, Thousand Oaks
    Lisa Rooney, 805-447-6437 (media)
    Arvind Sood, 805-447-1060 (investors)

(Logo: http://www.newscom.com/cgi-bin/prnh/20081015/AMGENLOGO)


'/>"/>
SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis
2. Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
3. Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
4. Study Demonstrates Efficacy of Pitavastatin in Elderly Patients
5. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
6. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
7. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
10. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
11. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)..., MISSISSAUGA,Ontario,Nov.24/PRNewswire-FirstCall/...adeveloperoftechnologyandproductstargetingtheimmun...kChimieS.A.S.("MerckChimie")isprogressingtothenext...arysilvercoatedparamagneticBeads("Beads"). ,, P...rthisyear,CardioGenicssuppliedMerckChimiewithitspr...
(Date:11/24/2009)..., FRANKLIN,Mass.,Nov.24/PRNewswire-FirstCall/--Ech...developingitsneedle-freeSymphony(TM)tCGMSystemasan...onitoring(tCGM)systemanditsPrelude(TM)SkinPrepSyst...rickT.Mooney,M.D.,ChairmanandChiefExecutiveOfficer...maceuticalsConference,sponsoredbytheNewYorkSociety...
(Date:11/24/2009)..., NORTHHOLLYWOOD,Calif.,Nov.24/PRNewswire-FirstCal...leadingnationalhospitalistphysiciangrouppracticeco...IPChospitalist,wasnamedby ACPHospitalist asoneofth...intheNovember2009issueofthemagazine. ,, Dr.Vaid...dcurrentlyservesasdirectorofhospitalmedicineatSt.M...
Breaking Medicine Technology:CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 2CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 3Echo Therapeutics to Present at the New York Society of Security Analysts' 13th Annual Biotech and Specialty Pharmaceuticals Conference 2IPC The Hospitalist Company's Philip Vaidyan, M.D. Named a Top Hospitalist of 2009 2Cell Biosciences Completes Acquisition of Alpha Innotech 5802 1Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference 5797 1Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference 5797 2Gene Variants Behind Vulnerability to Yeast Infections 60280 1Gene Variants Behind Vulnerability to Yeast Infections 60280 2Gene Variants Behind Vulnerability to Yeast Infections 60280 3
...ng CIMZIA,s long-term benefits and value in,modera... American College,of Gastroenterology (ACG), ORLA...this week by UCB at the American College of Gastro...IMZIA(R) (certolizumab pegol) - the,only PEGylated...ovides,sustained improvement in symptoms with stab...
... 7 , - 125 Patient, Prospective Randomized Placeb...gnificant Improved Overall Survival, Bavarian Nor...m the,therapeutic prostate cancer vaccine candidat...he recently entered partnership with the National,...om the Phase II prospective randomized placebo-con...
Other Medicine Technology:CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 2CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 3CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 7CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 8CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 9Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 2Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 3Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 4Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 5
(Date:11/24/2009)... The molecular cause of inflammatory bowel d...esented at the upcoming 2009 Advances in Inflammat...s Foundation’s Clinical & Research Confe...y identify a causative mutation for Crohn’s ...Vocus) November 24, 2009 -- The molecular cause of...
(Date:11/24/2009)...s,Nov.24/PRNewswire/--NIP,Inc.todayannouncedtheacq...tion,sleadingexecutivecompensationandbenefitplanpr...ionalofficesinLosAngeles,Milwaukee,Boston,Chicagoa...enownedexpertintheexecutivebenefitsindustry. ,,...readyhassignificantmarketpresence,"statesBillPollo...
(Date:11/24/2009)...NO,Calif.,Nov.24/PRNewswire/--Nextmonth,UnitedHeal...edathelpingHispanic-Americanseniorsunderstandtheba...ragedtotakeafreeZumba®Goldclass,aLatin-infuse...a,cumbia,rumba,andtango. ,, UnitedHealthcarewil...ortableandengagedwhenlearningabouttheirhealthcareo...
(Date:11/24/2009)...Nov.24/PRNewswire/--TheUnionLaborLifeInsuranceComp...dwithVSP(®),()thenation,slargestvisionbenefit...ceproductstounions,uniontrustfunds,unionemployersa...tsofferingservicesincludingcomprehensiveeyeexams,b...howimportantqualityeyecareis,"statedBruceSmith,Nat...
(Date:11/24/2009)...lement may help ward off peripheral artery diseas...(HealthDay News) -- Among people aged 75 and older...vent heart attacks, stroke or death, a new study f... herbal remedy might help prevent the leg-circulat...wever. , Ginkgo contains nutrients called flavo...
Breaking Medicine News(10 mins):Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 2Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 3Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 4Health News:NIP Acquires San Diego Executive Benefits Firm 2Health News:UnitedHealthcare To Offer Seniors Hispanic-Centered Medicare Education Seminars Combined With a Latin-Themed Fitness Program 2Health News:Union Labor Life & VSP Vision Care Align to Offer Vision Insurance Products 2Health News:Ginkgo Won't Prevent Heart Attack, Stroke in Elderly 2Health News:Ginkgo Won't Prevent Heart Attack, Stroke in Elderly 3
...ws Great for Moms and Babies, Bad for Mercury Fear...,seafood consumption guidelines for pregnant women...ers, Healthy Babies Coalition (HMHB), David,Martos...y swung back in the,direction of common sense. For...
...d Center for Geriatric Nursing Excellence in the U...r Hartford centers in the nation, have been funded... nurses have the most recent evidence-based guidel...ic Nursing Collaborative, are in the UI College of...
....J., Oct. 4 Understanding and Treating,Depression...ion produced by,the Multiple Sclerosis Association...ce on depression for both patients and families af...h topics as,the hidden symptoms of depression; war...
...7 National IPF Awareness Week on Capitol Hill Driv...dly Lung Disease, SAN JOSE, Calif., Oct. 4 The C...ced that the success of its fifth,annual National ...fibrosis (IPF), a progressive and ultimately fatal...
...on, wellness, and incentive system meets crucial n...et, FRANKLIN, Tenn., Oct. 4 Fontis Healthcare Se...d incentive support platform for,Group Health Savi...se of HSAs for employers, employees, and insurance...
...., Oct. 4 The following is a,statement regarding ...eople,store their health information online:, It ...le and other IT,leaders plan to develop personal h...Having ready access to your own,health information...
Other Medicine News:Health News:Consumer Group Statement on Seafood and Health: 'We Told You So' 2Health News:Multiple Sclerosis Association of America Publishes Booklet about Depression in Multiple Sclerosis 2Health News:CPF Urges Congress to Increase Funding for IPF Research in 2009 Federal Budget 2Health News:CPF Urges Congress to Increase Funding for IPF Research in 2009 Federal Budget 3Health News:CPF Urges Congress to Increase Funding for IPF Research in 2009 Federal Budget 4Health News:Fontis Health Launches Online HSA Support System 2Health News:Statement Regarding Microsoft's Announcement of New Services to Help People Store Their Health Information Online 2
...UHTS), Analyst GT delivers unsurpassed multimode a...sfer of assays into screening from assay developme...yst AD and HT, fluorescence intensity, fluorescenc...scence, absorbance, as well as providing seamless ...
...Analyst HT smoothes the transfer of assays into HT...y performance of Analyst AD, fluorescence intensit...cence, luminescence, absorbance. Optimized for se...uding those from Beckman Coulter, Zymark, CRS and ...
...lopment and basic research, including a simple ins...ime required to move assays into HTS. Specifically...ment laboratories, Analyst AD delivers unparallele..., Fluorescence Polarization, Time-Resolved Fluores...
...oplate based multi-detection reader which incorpor...orescence Polarization , Fluorescence Intensity ,...minescence (flash and glow) , Absorbance ,It i...dioactive labeled applications:, , Ca2+ Measuremen...
Medicine Products: